Glucotrack Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Glucotrack Inc (GCTK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Glucotrack Inc vs Its Competitors
- Scale: Glucotrack Inc ranks #212 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Glucotrack Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Glucotrack Inc | - | - | - | Yes |
| Competitors combined (9) | ||||
| High-Confidence Competitors (8) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GCTK Stock Performance relative to its Competitors
GCTK Stock Performance relative to High-Confidence Competitors
GCTK Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Dexcom Inc | 282.9% | Outperformed |
| 2 | Movano Inc | 282.9% | Outperformed |
| 3 | Senseonics Holdings Inc | 282.9% | Outperformed |
| 4 | Medtronic Plc | 282.9% | Outperformed |
| 5 | Endra Life Sciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Glucotrack Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Glucotrack Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Glucotrack Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Glucotrack Inc |
0.05 | - |
 Abbott Laboratories |
191,605.90 | 46,585.00 |
 Medtronic Plc |
130,823.18 | 37,542.00 |
 Dexcom Inc |
30,453.73 | 5,104.90 |
 Senseonics Holdings Inc |
496.87 | 47.15 |
 Movano Inc |
125.57 | 4.44 |
| SUBTOTAL | 353,632.39 | 89,308.81 |
Sign in to see all competitors of Glucotrack Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Glucotrack Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Glucotrack Inc's Competitors Named by the Company
Competitive relationships identified from Glucotrack Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Medtronic | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| DexCom | Company report | 85% |
| Usbc Inc | Company report | 85% |
| KNW | Company report | 85% |
| Mindray DS USA | Company report | 85% |
| Movano Inc | Company report | 85% |
| Ascensia | Company report | 85% |
| LifeScan, Inc. | Company report | 85% |
| Sterling Medical Devices | Company report | 85% |
| Insulet Corp | Company report | 85% |
| MiniMed | Company report | 85% |
| Bayer Corporation | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| Roche | Company report | 85% |
| Senseonics Holdings Inc | Company report | 85% |
| Universal Biosensors Inc | Company report | 85% |
| Nemaura Medical Inc | Company report | 85% |
| Vivani Medical Inc | Company report | 85% |
| Dariohealth Corp | Company report | 85% |
Company report basis, confidence, active dates and source counts for Glucotrack Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Glucotrack Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Abbott Laboratories | Diabetes Care 16.79 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Dexcom Inc | Reportable 100.00 % |
| Movano Inc | AI Platform and Services 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Glucotrack Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Glucotrack Inc | 0 | - | 554,600 |
| Abbott Laboratories | 191,606 | 405,087 | 47,174 |
| Medtronic Plc | 130,823 | 395,179 | 55,463 |
| Dexcom Inc | 30,454 | 459,901 | 89,432 |
| Senseonics Holdings Inc | 497 | 357,174 | -828,720 |
| Movano Inc | 126 | 110,875 | -691,300 |
| PEERS TOTAL | 353,632 | 403,073 | 87,817 |
Glucotrack Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Abbott Laboratories | Non-US 57.70 % |
| Medtronic Plc | United States 49.83 % |
| Dexcom Inc | United States 72.13 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Glucotrack Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Glucotrack Inc's industry classification, broader than the peer set above. Market cap in millions of $.Glucotrack Inc ranks #212 of 218 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 616, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 161,785 | 13.52 % |
| 2 | Medtronic Plc | 130,823 | 10.94 % |
| 3 | Stryker Corp | 125,786 | 10.51 % |
| 4 | 3m Company | 96,722 | 8.09 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Medline Inc | 1,234 | 5.2% |
| 212 | Glucotrack Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Glucotrack Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Glucotrack Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 207 | Bone Biologics Corporation | 1 | -83.54 % |
| 208 | Encision Inc | 0 | -93.45 % |
| 209 | Catheter Precision Inc | 0 | - |
| 210 | Ir med Inc | 0 | - |
| 211 | Nuwellis Inc | 1,234 | 12.3% |
| 212 | Glucotrack Inc | 0 | -95.02 % |
| 213 | Therapeutic Solutions International Inc | 1,234 | 12.3% |
| 214 | Omnia Wellness Inc | 1,234 | 12.3% |
| 215 | Allurion Technologies Inc | 1,234 | 12.3% |
| 216 | Better Therapeutics Inc | 1,234 | 12.3% |
| 217 | Bionik Laboratories Corp | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Glucotrack Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Glucotrack Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 0.0x | 37.6x | -37.6x |
| EV / EBITDA | -0.2x | 17.9x | -18.1x |
| P/B | 0.1x | 4.6x | -4.5x |
| Return on Equity | 1,114.03 % | industry aggregate | 1,102.05 % |
| Return on Invested Capital | 496.12 % | -6.81 % (avg) | 502.93 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Glucotrack Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | -1,679.25 % | -3,262.02 % | - | - | - | - | - |
| Return on Invested Capital | - | - | 14.89 % | 29.32 % | 77.75 % | 84.13 % | - | 158.67 % |
| P/E | 922.1x | - | - | - | - | - | - | 0.0x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Glucotrack Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Glucotrack Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.8% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Glucotrack Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 616 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Glucotrack Inc's dedicated Suppliers and Customers pages, not here.
Glucotrack Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Glucotrack Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Glucotrack Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 1,102.1 points above the industry aggregate.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Trades at a lower P/E than the industry average (0.0x vs 37.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (33.30 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Glucotrack Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Glucotrack Inc | 1.13 | 1.18 | 4.00 |
| Abbott Laboratories | 0.42 | 1.50 | 0.44 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Dexcom Inc | 0.46 | 1.82 | 0.46 |
| Senseonics Holdings Inc | 2.92 | 5.26 | 0.62 |
| Movano Inc | 1.14 | 1.55 | 0.01 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Glucotrack Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Glucotrack Inc | Q2 2026 | - | - |
| Abbott Laboratories | Q2 2026 | +13.0 % | -47.8 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Dexcom Inc | Q3 2026 | +11.3 % | -3.1 % |
| Senseonics Holdings Inc | Q2 2026 | +117.8 % | - |
| Movano Inc | Q2 2026 | +3,590.3 % | - |
| PEERS TOTAL | +13.3 % | +240.2 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Glucotrack Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Glucotrack Inc | Q2 2026 | - | - |
| Abbott Laboratories | Q2 2026 | +9.7 % | -1.0 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Dexcom Inc | Q3 2026 | +0.6 % | -34.3 % |
| Senseonics Holdings Inc | Q2 2026 | +67.9 % | +75.0 % |
| Movano Inc | Q2 2026 | - | - |
Glucotrack Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Glucotrack Inc | 151.40% | 843.28% | 1,114.03% |
| Abbott Laboratories | 5.56% | 6.45% | 10.41% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Dexcom Inc | 15.47% | 18.92% | 36.56% |
| Senseonics Holdings Inc | - | - | - |
| Movano Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Glucotrack Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Glucotrack Inc | 0.00 | - |
| Abbott Laboratories | 35.35 | 4.11 |
| Medtronic Plc | 299.41 | 3.48 |
| Dexcom Inc | 31.26 | 5.97 |
| Senseonics Holdings Inc | - | 10.54 |
| Movano Inc | - | 28.31 |
| PEERS AVERAGE | 18.17 | 3.96 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.